These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19716440)

  • 1. Incidence and nature of infectious disease in patients treated with anti-TNF agents.
    Raychaudhuri SP; Nguyen CT; Raychaudhuri SK; Gershwin ME
    Autoimmun Rev; 2009 Dec; 9(2):67-81. PubMed ID: 19716440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of biologic agents on infectious diseases.
    Saketkoo LA; Espinoza LR
    Infect Dis Clin North Am; 2006 Dec; 20(4):931-61, viii. PubMed ID: 17118297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
    Moiton MP; Richez C; Dumoulin C; Mehsen N; Dehais J; Schaeverbeke T
    Clin Microbiol Infect; 2006 Dec; 12(12):1151-3. PubMed ID: 17121619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [TNF inhibitors: a new therapeutic perspective in chronic inflammatory diseases in rheumatology?].
    Fenner H
    Z Rheumatol; 1995; 54(3):158-64. PubMed ID: 7660686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
    Sfikakis PP
    Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha.
    Edwards CK; Zhou T; Zhang J; Baker TJ; De M; Long RE; Borcherding DR; Bowlin TL; Bluethmann H; Mountz JD
    J Immunol; 1996 Aug; 157(4):1758-72. PubMed ID: 8759766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use.
    Mufti AH; Toye BW; Mckendry RR; Angel JB
    Diagn Microbiol Infect Dis; 2005 Nov; 53(3):233-8. PubMed ID: 16249064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-mediated inflammatory disease.
    Bradley JR
    J Pathol; 2008 Jan; 214(2):149-60. PubMed ID: 18161752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated administration of a F(ab')2 fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels.
    Boekstegers P; Weidenhöfer S; Zell R; Pilz G; Holler E; Ertel W; Kapsner T; Redl H; Schlag G; Kaul M
    Shock; 1994 Apr; 1(4):237-45. PubMed ID: 7735957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential target of infliximab in autoimmune and inflammatory diseases.
    Atzeni F; Doria A; Carrabba M; Turiel M; Sarzi-Puttini P
    Autoimmun Rev; 2007 Sep; 6(8):529-36. PubMed ID: 17854744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.
    Strangfeld A; Listing J
    Best Pract Res Clin Rheumatol; 2006 Dec; 20(6):1181-95. PubMed ID: 17127203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
    Fiorino G; Allez M; Malesci A; Danese S
    Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune diseases induced by TNF-targeted therapies.
    Ramos-Casals M; Brito-Zerón P; Soto MJ; Cuadrado MJ; Khamashta MA
    Best Pract Res Clin Rheumatol; 2008 Oct; 22(5):847-61. PubMed ID: 19028367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome.
    Jit M; Henderson B; Stevens M; Seymour RM
    Rheumatology (Oxford); 2005 Mar; 44(3):323-31. PubMed ID: 15585509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
    Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
    Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-alpha blockade and tuberculosis: better look before you leap.
    Arend SM; Breedveld FC; van Dissel JT
    Neth J Med; 2003 Apr; 61(4):111-9. PubMed ID: 12852719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why does tumor necrosis factor targeted therapy reactivate tuberculosis?
    Ehlers S
    J Rheumatol Suppl; 2005 Mar; 74():35-9. PubMed ID: 15742463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
    Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N
    Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.